MENU

TEM Tempus AI Inc. Forecast, Technical & Fundamental Analysis

Tempus AI Inc is a technology company... Show more

A.I.Advisor
Oct 30, 2026

Tempus AI (TEM) Stock Forecast: AI-Powered Precision Medicine at a Key Inflection Point

Key Takeaways

  • Upcoming catalysts include the company's third-quarter 2026 earnings report on November 2 and the pending acquisition of Personalis, which would expand its molecular residual disease (MRD) testing capabilities.
  • Tempus AI is strategically positioned at the intersection of AI-enabled diagnostics and data licensing, reinforced by a proprietary dataset exceeding 500 petabytes and a commercial pipeline with total contract value above $1.1 billion.
  • Industry tailwinds include accelerating adoption of genomic sequencing in oncology and rising pharmaceutical demand for real-world data, while reimbursement for AI-based algorithms remains a structural headwind.
  • The business is sensitive to healthcare reimbursement policy, regulatory approvals from the U.S. Food and Drug Administration (FDA), and the pace of large pharma data-licensing contract renewals.
  • Analyst sentiment is broadly constructive but mixed, with a consensus "Buy" rating and an average price target near $75, set against a wide range from roughly $35 to $100 reflecting divergent views on execution and valuation.
  • Key risks include the timing of MRD commercialization, the durability of data-contract renewals, and the path to sustained profitability and positive free cash flow.
  • For more information on this ticker's Major News, Today's Price Move, Price Targets, and Earnings, explore the additional pages for deeper data and analysis.
  • Readers can also explore Trending AI Robots for AI-driven market tools designed to complement independent research.

Strategic Positioning and Competitive Outlook

Tempus AI operates a two-sided platform that combines molecular diagnostics with a fast-growing data and applications segment. Its Diagnostics business performs genomic testing for patients and providers, while its Data and Applications arm licenses de-identified, outcome-linked datasets and AI tools to pharmaceutical companies and researchers. This structure creates a reinforcing "data flywheel," in which each new test and partnership expands the dataset that makes its models more valuable.

The company's competitive moat rests on scale and integration. It is connected with more than 5,500 hospitals and over 8,500 oncologists, giving it distribution and workflow access that is difficult to replicate. Management has also expanded beyond oncology into digital pathology, cardiology, and neuroscience, broadening the addressable market. Strategically, Tempus has deepened multi-year collaborations with major pharmaceutical partners, signaling a shift from transactional data licensing toward long-term, model-building relationships. Over the medium term, the company's ability to convert regulatory approvals into higher reimbursement and to scale its MRD testing franchise will be central to its market positioning.

Major Catalysts Ahead

The most immediate catalyst is the third-quarter 2026 earnings release on November 2, where investors will focus on revenue trajectory against full-year guidance of approximately $1.595 billion to $1.605 billion, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of roughly $65 million, and commentary on the Personalis acquisition, which is expected to close into 2027.

Regulatory milestones also loom large. FDA approval of the tumor-only xT companion diagnostic is expected to lift average selling prices by an estimated $200 per test, translating to roughly $85 million in annual revenue uplift beginning in 2027. A potential approval of the xF liquid biopsy assay in the latter half of 2027 could add a further estimated $550 million in annual selling-price uplift, according to management commentary. Internationally, the xR RNA assay recently received European Union IVDR certification, opening additional geographic opportunity.

Analyst activity has turned more optimistic heading into year-end. Several firms raised price targets in October 2026, including Canaccord Genuity ($80 to $95), Guggenheim ($65 to $92), Bank of America ($52 to $75), and J.P. Morgan ($45 to $70). Consensus coverage now averages a "Buy" rating with a mean 12-month price target near $75, though the dispersion from roughly $35 to $100 underscores continued debate over valuation and execution risk.

Industry and Macroeconomic Forces

Tempus AI's trajectory is closely tied to healthcare technology adoption and the pharmaceutical research-and-development cycle. Rising adoption of comprehensive genomic profiling and precision oncology supports volume growth in its core diagnostics business, while demand for real-world data among drug developers underpins the higher-margin data segment.

Macroeconomic factors matter indirectly. Interest rates influence the valuation of growth-stage, cash-flow-negative companies and the cost of capital for acquisition financing. The company has already refinanced debt through a $460 million convertible note offering, which management says will reduce annual interest expense by more than $30 million. Inflation and labor costs affect laboratory operating expenses, while reimbursement policy and payer willingness to cover AI-driven diagnostic algorithms represent a structural regulatory variable. Finally, geopolitical and supply-chain dynamics can influence sequencing costs and pharmaceutical research budgets, though the company's core demand drivers remain domestic clinical and pharmaceutical adoption trends.

Trend Prediction Engine

Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF (exchange-traded fund), or other asset may trend bullish, bearish, or sideways over the next week or month. Designed to surface developing trends, evaluate possible breakouts or reversals, and support exploration across a broad range of tradable instruments, the platform offers searchable prediction categories, historical context, and alert-oriented functionality. For investors monitoring a dynamic name like Tempus AI, the engine provides a neutral, data-driven complement to fundamental analysis.

2026 Outlook and Long-Term Themes to Watch

Looking toward 2026 and beyond, Tempus AI's outlook centers on several structural themes. First, the transition from high-growth investment toward scaled profitability remains the central financial narrative, with management targeting positive adjusted EBITDA and improved cash generation as revenue scales. Second, MRD testing represents a potentially large market-expansion opportunity, though commercialization is being deliberately paced to align with reimbursement economics.

Margin sustainability will depend on laboratory automation, favorable pricing from regulatory approvals, and the mix shift toward higher-margin data licensing. Technology transitions, including the deployment of foundation models built with pharmaceutical partners and the launch of AI pathology tools such as Paige Predict, could broaden the company's product ecosystem beyond its historical oncology core. Competitive threats from established diagnostics firms and large technology companies entering healthcare AI warrant monitoring.

Capital allocation priorities, including the pending Personalis transaction and debt refinancing, will shape the balance sheet over the coming years. Consensus expectations currently model revenue growth in the mid-teens to mid-twenties percentage range annually, with profitability anticipated to inflect over the next several years. These assumptions, rather than any single quarterly result, are likely to define how long-term sentiment around the stock evolves.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
ADX.X0.0453260.000995
+2.24%
heyAura cryptocurrency
GAS.X0.961242-0.001281
-0.13%
Gas cryptocurrency
TAO.X192.174160-0.281876
-0.15%
Bittensor cryptocurrency
OSMO.X0.029530-0.001137
-3.71%
Osmosis cryptocurrency
DF.X0.000154-0.000078
-33.65%
dForce cryptocurrency

TEM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TEM has been loosely correlated with SDGR. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if TEM jumps, then SDGR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEM
1D Price
Change %
TEM100%
-6.30%
SDGR - TEM
62%
Loosely correlated
-3.16%
TXG - TEM
52%
Loosely correlated
+0.54%
SOPH - TEM
47%
Loosely correlated
-10.58%
GEHC - TEM
40%
Loosely correlated
-2.12%
CERT - TEM
36%
Loosely correlated
-4.47%
More

Groups containing TEM

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEM
1D Price
Change %
TEM100%
-6.30%
Services to the Health Industry
industry (41 stocks)
19%
Poorly correlated
-4.19%
Health Services
industry (238 stocks)
6%
Poorly correlated
-3.34%
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Industry
N/A
Address
600 West Chicago Avenue
Phone
+1 800 976-5448
Employees
3800
Web
https://www.tempus.com
Tempus AI (TEM) Stock Forecast: AI-Powered Precision Medicine at a Key Inflection Point